AIM ImmunoTech Inc. (AIM) stock
Close on Nov 11, 2026Market cap $4.52MP/E –Yield –
AIM ImmunoTech Inc. saw revenue fall 21.5% to $95.00K over the twelve months to Jun 30, 2026. At the latest close the market valued the company at $4.52M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $4.52M
- P/E ratio
- –
- Price to sales
- 47.55
- Price to book
- 0.58
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $95.00K
- Net income
- -$14.27M
- EPS, diluted
- -$8.62
- Book value per share
- $0.45
- Diluted shares
- 17M
Trading
- Previous close
- $0.14
- Open
- $0.15
- Day's range
- $0.14 – $0.15
- Volume
- 684,945
- Average volume (20 days)
- 548,679
- Beta (5 years)
- 0.83
- 52-week range
- $0.12 – $1.88
- RSI (14 days)
- 38.8
- Volatility (1 year)
- 202.7%
- Relative volume
- 0.20×
- WACC
- 10.3%
Market cap history
Month-end market cap since 2011, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | AIM | S&P 500 | Difference | AIM per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -17.6% | -2.4% | −15.1 pts | ||
| 3 months | -41.7% | -1.2% | −40.6 pts | ||
| Year to date | -86.4% | +12.3% | −98.7 pts | ||
| 1 year | -90.3% | +12.4% | −102.7 pts | ||
| 3 years | -99.6% | +78.8% | −178.4 pts | -84.6% | +21.4% |
| 5 years | -99.9% | +75.2% | −175.1 pts | -75.4% | +11.9% |
| 10 years | -100.0% | +311.1% | −411.1 pts | -63.8% | +15.2% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases AIM ImmunoTech filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- Update
- Results
- News
- News
About AIM ImmunoTech
Biological Products, (No Diagnostic Substances)
AIM ImmunoTech Inc. is an immuno-pharma company focused on research and development of therapeutics to treat multiple types of cancer, viral diseases, and immune-deficiency disorders with inadequate or unmet treatments. Its primary products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA molecule being evaluated across various solid tumor types, including late-stage pancreatic cancer, as well as viral illnesses and immune disorders. The company aims to develop treatments for healthcare providers and patients facing severe diseases, including post-COVID conditions and chronic fatigue syndrome.
Company profile, executives and historyAIM ImmunoTech stock: common questions
What is AIM ImmunoTech's stock price?
AIM closed at $0.15 on Nov 11, 2026, up 7.54% on the day. Over the past 52 weeks it traded between $0.12 and $1.88.
What is AIM ImmunoTech's market cap?
AIM ImmunoTech was worth $4.52M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is AIM's P/E ratio?
AIM ImmunoTech lost money over fiscal 2025 (diluted EPS -$8.62), so it has no meaningful P/E ratio.
How much revenue does AIM ImmunoTech make?
AIM ImmunoTech reported revenue of $95.00K for the twelve months to Jun 30, 2026, down 21.5% from a year earlier.
Does AIM ImmunoTech pay a dividend?
No. AIM ImmunoTech has not paid a cash dividend over the last twelve months.
How has AIM stock performed over the past year?
Including dividends, AIM returned -90.3% over the past year, against +12.4% for the S&P 500.
How many AIM shares are sold short?
1M shares were sold short at the latest FINRA report, 3.78% of the float, or 2.5 days of average trading volume.
Who are AIM ImmunoTech's competitors?
Companies most similar to AIM ImmunoTech by business, industry and size include INMB, ABPO, ARTV, ATYR, HIND.
See a number that looks wrong?